By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
Vertex (VRTX) To Announce Second Quarter 2016 Financial Results On July 27 7/14/2016 10:53:03 AM
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines 7/14/2016 6:31:45 AM
Boston Filmmaker Plans to Make a Movie About the Early Days of Vertex (VRTX) 7/12/2016 6:45:43 AM
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology 7/6/2016 6:25:31 AM
Claire's Place Foundation Receives Grant From Vertex (VRTX) 6/22/2016 7:42:43 AM
Vertex (VRTX) Announces Presentations Of Data For KALYDECO (Ivacaftor) And ORKAMBI® (Lumacaftor/Ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference 6/10/2016 10:46:04 AM
Vertex (VRTX) To Present At The Goldman, Sachs & Co. Healthcare Conference On June 7 6/1/2016 4:21:19 PM
Vertex (VRTX) Release: FDA Accepts For Priority Review Supplemental New Drug Application For The Use Of ORKAMBI (Lumacaftor/Ivacaftor) In Children With Cystic Fibrosis Ages 6 To 11 Who Have Two Copies Of The F508del Mutation 5/31/2016 12:42:10 PM
Spero Acquires Novel Gyrase Inhibitors From Vertex (VRTX) 5/25/2016 6:39:37 AM